Efficacy and Safety of Ixekizumab versus Adalimumab with and Without Concomitant Conventional Synthetic Disease-Modifying Antirheumatic Drugs (DMARD) in Biologic DMARD-Naive Patients with Psoriatic Arthritis: 52-Week Results
File version
Author(s)
Sebba, Anthony
Ruderman, Eric
Gellett, Amanda
Sapin, Christophe
Sprabery, Aubrey
Liu-Leage, Soyi
Pillai, Sreekumar
Reis, Paulo
Nash, Peter
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
File type(s)
Location
Virtual
License
Abstract
Background/Purpose: Ixekizumab (IXE), a high-affi nity monoclonal antibody selectively targeting IL-17A, was superior to adalimumab (ADA) at Week (Wk) 24 for simultaneous achievement of ACR50 and 100% improvement from baseline in Psoriasis Area and Severity Index (PASI 100); (primary endpoint) in patients (pts) with active PsA from SPIRIT-H2H. SPIRIT-H2H had 2 major secondary endpoints and achieved both: noninferiority of IXE to ADA for ACR50 and superiority of IXE to ADA for PASI 100, at Wk 24.The aim was to determine how concomitant conventional synthetic (cs) DMARD use affects safety and effi cacy of IXE and ADA in prespecifi ed subgroups defi ned by biologic monotherapy, concomitant MTX use, and concomitant csDMARD use through Wk 52 in SPIRIT-H2H. Methods: SPIRIT-H2H was a 52-wk, multicenter, randomized, open-label, assessor-blinded, parallel-group study evaluating the effi cacy and safety of IXE vs ADA in adults with PsA and naïve to biologic DMARDs. Pts were required to have active PsA fulfi lling Classifi cation for Psoriatic Arthritis (CASPAR) criteria and ≥3/68 tender and ≥3/66 swollen joints, ≥3% plaque psoriasis (PsO) body surface area (BSA) involvement, no prior treatment with biologic DMARDs, and with prior inadequate response to ≥1 csDMARD (but not necessarily current treatment with csDMARDs). Randomization (1:1) was stratifi ed by concomitant use of csDMARD and the presence/absence of moderate-to-severe PsO (baseline: BSA≥10% + PASI≥12, + static Physician’s Global Assessment≥3). Pts (N=566) received IXE/ADA through 52 wks according to the labelled dose dependent on presence/absence of moderate-to-severe PsO. In this prespecifi ed subgroup analysis by presence/absence of csDMARDs, effi cacy outcomes through Wk 52 were com-pared between IXE and ADA using logistic regression models and Fisher’s exact tests. Missing data were imputed using non-responder imputation. Results: At baseline, 167/283 IXE- and 169/283 ADA-treated pts had concomitant MTX use. Of these, 9.0% (15/167) and 7.1% (12/169) treated with IXE and ADA, respectively, were taking an additional csDMARD (sulfasalazine, cyclosporine, or lefl unomide). A signifi cantly greater proportion of pts on IXE vs ADA achieved the primary endpoint or PASI 100 when used as monotherapy or in combination with csDMARD (Figs. 1A and 1C). At Wk 52, the proportion of pts achieving ACR50 was not statistically different between IXE and ADA, regardless of monotherapy or concomitant csDMARD use (Fig. 1B). A signifi cantly higher proportion of pts achieved minimal disease activity (MDA) on IXE compared to ADA in the monotherapy subgroup (49% vs 33%), while the response rates were similar in both combination subgroups (Fig. 1D). These data support consistent ACR50, PASI 100, and MDA response for IXE across all 3 subgroups. There were no signifi cant differences in safety data across the 3 subgroups for either IXE or ADA (Fig. 2). Conclusion: As with prior studies, consistent effi cacy across multiple PsA disease-specifi c endpoints was observed with IXE in SPIRIT-H2H, regardless of whether IXE was taken as monotherapy or in combination with MTX or another csDMARD. Both agents were well tolerated, with no unexpected safety signals.
Journal Title
Conference Title
Arthritis & Rheumatology
Book Title
Edition
Volume
72
Issue
S10
Thesis Type
Degree Program
School
Publisher link
DOI
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject
Clinical sciences
Science & Technology
Life Sciences & Biomedicine
Rheumatology
Persistent link to this record
Citation
Smolen, J; Sebba, A; Ruderman, E; Gellett, A; Sapin, C; Sprabery, A; Liu-Leage, S; Pillai, S; Reis, P; Nash, P, Efficacy and Safety of Ixekizumab versus Adalimumab with and Without Concomitant Conventional Synthetic Disease-Modifying Antirheumatic Drugs (DMARD) in Biologic DMARD-Naive Patients with Psoriatic Arthritis: 52-Week Results, Arthritis & Rheumatology, 2020, 72, pp. 707-709